Background and Aims: Gestational diabetes (GD) identifies a pregnancy with high obstetrical risk due to the possible complications that may appear and which are associated with significant perinatal mortality and morbidity. The role of HbA1c in diagnosing GD is still debatable. Our aim was to evaluate the clinical utility of HbA1c assessed in the second trimester of pregnancy (before performing the oral glucose tolerance test - OGTT) in establishing the macrosomia risk, and also for diagnosing GD. Material and methods: This was an observational study on a group of 165 pregnant women followed from the first trimester of pregnancy in whom we measured HbA1c in the second trimester, before running an OGTT with 100 grams of glucose and who delivered at term (37 - 41 weeks of pregnancy). Finally, HbA1c and OGTT were performed only in 132 women, these being the subjects of our study. Results: The average value of HbA1c was 4.85±1.23%. HbA1c was higher in the group having gestational diabetes (6.58±0.74%) in comparison to the group not having GD (4.52±0,80%). The Receiver Operating Characteristic (ROC) curve for HbA1c determined in the second trimester, for diagnosis of GD, has an area under the curve (AUC) of 0.939. Conclusions: HbA1c value could be considered as a sensitive and specific predictive factor in appreciating the macrosomia risk and could be set as an extra criterion in GD diagnosis.

Objectives: The aim of the study was to calculate the prevalence rates and risk ofappearance of Dupuytrèn disease in diabetic patients with both type-1 (T1DM) andtype-2 diabetes (T2DM). Material and Method: 384 patients were analysed, ofwhich 47 had T1DM, 140 had T2DM and 197 were non-diabetic controls. Diabeticpatients were followed at the Clinical Center for Diabetes, Nutrition and MetabolicDisease of the Emergency Clinical County Hospital and Department of Dermatologyin Oradea, all of them having a diabetes duration of at least 5 years. Results and Conclusions: The risk of Dupuytrèn’s disease is over 4.5 times greater in patientswith type-2 diabetes. The risk of Dupuytrèn’s disease is 3-6 times greater in patientswith micro-vascular complications.

Background and Aims. We aimed to analyze the complications and mortality of acute abdomen cases in diabetic patients compared to non-diabetic patients. Materials and Method. This observational, retrospective, cohort study was conducted between 2008 - 2011, on a total of 4021 cases with acute abdomen admitted to the Surgical Ward I of the Clinical County Emergency Hospital Oradea. Of these, 488 were diabetic patients and 3533 non-diabetics. Results. Women represented the majority in both groups (62.24% respectively 58.40%). Entero-mesenteric infarction and acute pancreatitis were more common in diabetic patients compared to non-diabetics. Peritonitis was more frequent in non-diabetics, with statistically significant difference (p = 0.0003). In diabetic patients the postoperative morbidity was 36.27%, significantly higher than in non-diabetic patients (14.43%). The mortality was significantly higher in diabetic patients than in nondiabetics (9.84% vs. 5.38%). Average length of stay in Surgical Ward I is 3.8 days. For non-diabetic patients, mean hospitalization for acute abdomen was 5.1 days, and for diabetics 7.8 days. Conclusions. This study showed important differences between diabetics and non-diabetic patients in the clinical evolution, complications, mortality and length of hospitalization.

Background and Aims: We evaluated fecal calprotectin values in patients with colorectal neoplasms undergoing surgery, comparatively in patients with and without diabetes mellitus. Material and Methods: We studied 40 patients operated for colorectal neoplasm, divided into two groups: one group of 20 patients with insulin-treated type 2 diabetes and another group of 20 patients without diabetes. Results: Patients had a high percentage of preoperative calprotectin test positivity (90%, 36 patients). A total of 19 patients in group 1 and 17 patients in group 2 had a positive calprotectin test. Postoperatively at 3 months, fecal calprotectin values remained elevated in 7 patients from group 1 and 4 patients from group 2. At 6 months postoperatively, fecal calprotectin values remained elevated in 2 patients from group 1 and 1 patient from group 2. Conclusions: Calprotectin values in faeces from patients with colorectal cancer were significantly increased, with a trend towards post-operatory normalization, slower in patients with diabetes. Fecal calprotectin value as a screening marker was almost equal compared to the hemoccult test, and better compared to that of the carcinoembryonic antigen.

Background and Aims